Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Rossier

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Critical Reviews in Oncology/Hematology|January 1, 2016
Recent advances in regional treatment of breast carcinomaJacques Bernier, Christine Rossier, Jean-Claude Horiot
Breast (Edinburgh, Scotland)|September 28, 2019
Postmastectomy radiotherapy in T1-2 patients with one to three positive lymph nodes - Past, present and futureFilip Kaššák, Christine Rossier, Cristina Picardi, et al.
European Journal of Pharmacology|April 16, 2013
Genomic classifications and radiotherapy for breast cancerAnna Britten, Christine Rossier, Naila Taright, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2012
Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and MetaanalysisVincent Dunet, Christine Rossier, Alfred Buck, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2011
Low-dose radiotherapy in indolent lymphomaChristine Rossier, Ulrike Schick, Raymond Miralbell, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 7, 2011
Voriconazole-induced periostitisChristine Rossier, Vincent Dunet, Frederic Tissot, et al.
Radiation Oncology (London, England)|August 24, 2012
Higher toxicity with 42 Gy in 10 fractions as a total dose for 3D-conformal accelerated partial breast irradiation: results from a dose escalation phase II trialCeline Bourgier, Catalina Acevedo-Henao, Ariane Dunant, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 31, 2025
Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trialThomas Brion, Mamadou Balde, Rodrigue Allodji, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Critical Reviews in Oncology/Hematology|January 1, 2016
Recent advances in regional treatment of breast carcinomaJacques Bernier, Christine Rossier, Jean-Claude Horiot
Breast (Edinburgh, Scotland)|September 28, 2019
Postmastectomy radiotherapy in T1-2 patients with one to three positive lymph nodes - Past, present and futureFilip Kaššák, Christine Rossier, Cristina Picardi, et al.
European Journal of Pharmacology|April 16, 2013
Genomic classifications and radiotherapy for breast cancerAnna Britten, Christine Rossier, Naila Taright, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2012
Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and MetaanalysisVincent Dunet, Christine Rossier, Alfred Buck, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2011
Low-dose radiotherapy in indolent lymphomaChristine Rossier, Ulrike Schick, Raymond Miralbell, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 7, 2011
Voriconazole-induced periostitisChristine Rossier, Vincent Dunet, Frederic Tissot, et al.
Radiation Oncology (London, England)|August 24, 2012
Higher toxicity with 42 Gy in 10 fractions as a total dose for 3D-conformal accelerated partial breast irradiation: results from a dose escalation phase II trialCeline Bourgier, Catalina Acevedo-Henao, Ariane Dunant, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 31, 2025
Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trialThomas Brion, Mamadou Balde, Rodrigue Allodji, et al.
Pageof 1